Actinium Pharmaceuticals, Inc.
ATNMAMEXHealthcare● Active
$1.06
$-0.02(-1.85%)
Market Cap$33257494
P/E Ratio—
52W High$1.945
52W Low$0.952
Actinium Pharmaceuticals, Inc. (ATNM) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ATNM · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 8, 2026EPS Actual
-$0.18
Est. -$0.22 · +18.2%
Revenue
—
Est. $0.00B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 8, 2026
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
ATNM reports quarterly as a AMEX-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 14, 2026 | -$0.20 | — | — | — | $0.04B | — |
| ▲ Q2 FY2026 | May 8, 2026 | -$0.22 | -$0.18 | +18.2% | — | $0.00B | — |
| ▼ Q1 FY2026 | Mar 30, 2026 | -$0.19 | -$0.19 | -1.8% | — | $0.00B | — |
| ▲ Q4 FY2025 | Nov 14, 2025 | -$0.25 | -$0.16 | +36.0% | $0.00B | $0.00B | +33.3% |
| ▲ Q3 FY2025 | Aug 8, 2025 | -$0.32 | -$0.22 | +31.3% | — | — | — |
| ▼ Q2 FY2025 | May 9, 2025 | -$0.26 | -$0.51 | -96.2% | — | — | — |
| ▲ Q1 FY2025 | Mar 31, 2025 | -$0.37 | -$0.21 | +43.2% | $0.00B | — | — |
| ▼ Q4 FY2024 | Nov 14, 2024 | -$0.35 | -$0.37 | -5.7% | — | — | — |
Q3 FY2026
Aug 14, 2026
EPS Actual
—
EPS Est.
-$0.20
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 8, 2026Beat
EPS Actual
-$0.18
EPS Est.
-$0.22
EPS Surpr.
+18.2%
Revenue
—
Q1 FY2026
Mar 30, 2026Miss
EPS Actual
-$0.19
EPS Est.
-$0.19
EPS Surpr.
-1.8%
Revenue
—
Q4 FY2025
Nov 14, 2025Beat
EPS Actual
-$0.16
EPS Est.
-$0.25
EPS Surpr.
+36.0%
Revenue
$0.00B
Q3 FY2025
Aug 8, 2025Beat
EPS Actual
-$0.22
EPS Est.
-$0.32
EPS Surpr.
+31.3%
Revenue
—
Q2 FY2025
May 9, 2025Miss
EPS Actual
-$0.51
EPS Est.
-$0.26
EPS Surpr.
-96.2%
Revenue
—
Q1 FY2025
Mar 31, 2025Beat
EPS Actual
-$0.21
EPS Est.
-$0.37
EPS Surpr.
+43.2%
Revenue
$0.00B
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
-$0.37
EPS Est.
-$0.35
EPS Surpr.
-5.7%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Q3 FY2026 | $-0.21 | $-0.21 | $-0.21 | 1 |
| Q2 FY2026 | $-0.21 | $-0.21 | $-0.21 | 1 |
| Q1 FY2026 | $-0.23 | $-0.23 | $-0.23 | 2 |
| Q4 FY2025 | $-0.19 | $-0.19 | $-0.19 | 2 |
| Q3 FY2025 | $-0.18 | $-0.18 | $-0.18 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2025 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2025 | $0.0B | $0.0B | $0.0B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 8, 2026 | +18.2% | $1.22 | $1.31 | +7.38% |
| ▼ Q1 FY2026 | Mar 30, 2026 | -1.8% | $1.03 | $0.99 | -3.88% |
| ▲ Q4 FY2025 | Nov 14, 2025 | +36.0% | $1.25 | $1.27 | +1.60% |
| ▲ Q3 FY2025 | Aug 8, 2025 | +31.3% | $1.56 | $1.54 | -1.28% |
| ▼ Q2 FY2025 | May 9, 2025 | -96.2% | $1.43 | $1.48 | +3.50% |
| ▲ Q1 FY2025 | Mar 31, 2025 | +43.2% | $1.81 | $1.61 | -11.05% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -5.7% | $1.71 | $1.65 | -3.51% |
| ▲ Q3 FY2024 | Aug 5, 2024 | +20.8% | $6.17 | $2.48 | -59.81% |
Q2 FY2026+7.38%
Report Date
May 8, 2026
EPS Beat/Miss
+18.2%
Price Before
$1.22
Price After
$1.31
Q1 FY2026-3.88%
Report Date
Mar 30, 2026
EPS Beat/Miss
-1.8%
Price Before
$1.03
Price After
$0.99
Q4 FY2025+1.60%
Report Date
Nov 14, 2025
EPS Beat/Miss
+36.0%
Price Before
$1.25
Price After
$1.27
Q3 FY2025-1.28%
Report Date
Aug 8, 2025
EPS Beat/Miss
+31.3%
Price Before
$1.56
Price After
$1.54
Q2 FY2025+3.50%
Report Date
May 9, 2025
EPS Beat/Miss
-96.2%
Price Before
$1.43
Price After
$1.48
Q1 FY2025-11.05%
Report Date
Mar 31, 2025
EPS Beat/Miss
+43.2%
Price Before
$1.81
Price After
$1.61
Q4 FY2024-3.51%
Report Date
Nov 14, 2024
EPS Beat/Miss
-5.7%
Price Before
$1.71
Price After
$1.65
Q3 FY2024-59.81%
Report Date
Aug 5, 2024
EPS Beat/Miss
+20.8%
Price Before
$6.17
Price After
$2.48
Avg Beat Reaction-12.63%
Avg Miss Reaction-1.30%
Beat Rate5 / 8 quarters
Largest Move-59.81% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ATNM ends December
Actinium Pharmaceuticals, Inc. (ATNM) most recently reported earnings on May 8, 2026 for Q2 FY2026, posting EPS of $-0.18 — beating the analyst consensus of $-0.22 by +18.2%. The next ATNM earnings date is expected around September 1, 2026.
Each quarter, investors track ATNM earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ATNM revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ATNM's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ATNM earnings · 5 questionsActinium Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. ATNM typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ATNM historically reports after market close (AMC).
ATNM earnings datewhen is ATNM earningsATNM next earnings datewhen does ATNM report earningsATNM earnings calendar
▸ Source: FMP · Actinium Pharmaceuticals, Inc. SEC filings · US GAAP · Actinium Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026